Salvage Ovarian FANG™ Vaccine + Carboplatinum

Stage IV Ovarian Cancer Clinical Trial

Official title:

Phase II Trial of Adjuvant Bi-shRNAfurin and GMCSF Augmented Autologous Tumor Cell Vaccine (FANG™) Integrated With Chemotherapy for Patients With Recurrent Cisplatinum Sensitive Ovarian Cancer Participating in Study CL-PTL 105

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT01867086
• Other study ID #: CL-PTL 110
• Status: Completed
• Phase: Phase 2
• Start date: June 2013
• Est. completion date: April 8, 2016

Study information

• Verified date: May 2018
• Source: Gradalis, Inc.
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This is a Phase II study of Vigil™ autologous tumor cell vaccine integrated with carboplatinum. All patients will have Vigil™ prepared and stored from ovarian tumor cells obtained at the time of primary surgical debulking. Patients meeting eligibility criteria will receive either carboplatinum alone (AUC 6/30 minute infusion) or carboplatinum (AUC 5/30 minute infusion) and taxol (175 mg/m2/3 hour infusion) one day prior to Vigil™ 1.0 x 10e7 cells/intradermal injection, once every 3 weeks.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 1
• Est. completion date: April 8, 2016
• Est. primary completion date: April 2016
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

1. Histologically confirmed papillary serous or endometrioid ovarian cancer.

2. Previous randomization to Gradalis, Inc. protocol CL-PTL 105; observation arm (Group B) or or patients with vaccine prepared for CL-PTL 105 but did not otherwise qualify.

3. Recurrent cisplatinum-sensitive disease (defined as the appearance of any measurable or evaluable lesion or as asymptomatic CA-125 levels greater than 100 u/mL at two consecutive measurements after a 6 month period after platinum treatment.

4. Successful manufacturing of 4 vials of Vigil™ vaccine.

5. Recovered from all clinically relevant toxicities related to prior therapies.

6. ECOG PS 0-2 prior to Vigil™ vaccine administration.

7. Normal organ and marrow function as defined below:

1. Absolute granulocyte count = 1,500/mm3

2. Absolute lymphocyte count = 200/mm3

3. Platelets = 100,000/mm3

4. Total bilirubin = 1.5 x ULN

5. AST(SGOT)/ALT(SGPT)/alkaline phosphatase = 2.5 x ULN

6. Creatinine < 1.5 mg/dL

8. Patients must be off all "statin" drugs for = 2 weeks prior to initiation of therapy.

9. Ability to understand and the willingness to sign a written informed protocol specific consent.

Exclusion Criteria:

1. Surgery involving general anesthesia, chemotherapy, radiotherapy, steroid therapy, or immunotherapy within 4 weeks prior to vaccination. Chemotherapy within 3 weeks prior to vaccination. Steroid therapy within 1 week prior to vaccination.

2. Patient must not have received any other investigational agents within 4 weeks prior to study entry.

3. Patients who require parenteral hydration of nutrition and have evidence of partial bowel obstruction or perforation.

4. Patients with history of brain metastases.

5. Patients with compromised pulmonary disease.

6. Short term (<30 days) concurrent systemic steroids = 0.25 mg/kg prednisone per day (maximum 7.5 mg/day) and bronchodilators (inhaled steroids) are permitted; other steroid regimens and/or immunosuppressives are excluded.

7. Prior splenectomy.

8. Prior malignancy (excluding nonmelanoma carcinomas of the skin and carcinoma in situ cervix) unless in remission for = 2 years.

9. Kaposi's Sarcoma.

10. Patients with peripheral neuropathy =2 (paclitaxel).

11. Uncontrolled infection or psychiatric illness/social situations that would limit compliance with study requirements.

12. Patients with known HIV.

13. Patients with chronic Hepatitis B and C infection.

14. Patients with uncontrolled autoimmune diseases.

Related Conditions & MeSH terms

• Ovarian Neoplasms
• Stage III Ovarian Cancer
• Stage IV Ovarian Cancer

Intervention

Biological:
• Vigil™ Vaccine
Patients meeting eligibility criteria will receive Vigil™ 1.0 x 10e7 cells/intradermal injection once every 3 weeks.

Drug:
• Carboplatinum
Patients meeting eligibility criteria will receive either carboplatinum alone (AUC 6/30 minute infusion) or carboplatinum (AUC 5/30 minute infusion) and taxol (175 mg/m2 3-hour infusion) one day prior to Vigil™ 1.0 x 10e7 cells/ intradermal injection, once every three weeks. At recurrence, patients allergic to carboplatinum will receive docetaxel 75 mg/m2/1 hour infusion, one day prior to Vigil™ 1.0 x 10e7 cells/intradermal injection every 3 weeks. Patients with stable disease (SD) or better and unable to tolerate continued chemotherapy will be allowed to continue Vigil™ alone for up to 12 cycles or as long as vaccine is available; conversely, patients with SD or better who exhaust Vigil™ supply may continue on chemotherapy alone.
• Carboplatinum and Taxol
Patients meeting eligibility criteria will receive either carboplatinum alone (AUC 6/30 minute infusion) or carboplatinum (AUC 5/30 minute infusion) and taxol (175 mg/m2 3-hour infusion one day prior to Vigil™ 1.0 x 10e7 cells/ intradermal injection, once every three weeks. At recurrence, patients allergic to carboplatinum will receive docetaxel 75 mg/m2/1 hour infusion, one day prior to Vigil™ 1.0 x 10e7 cells/intradermal injection every 3 weeks. Patients with stable disease (SD) or better and unable to tolerate continued chemotherapy will be allowed to continue Vigil™ alone for up to 12 cycles or as long as vaccine is available; conversely, patients with SD or better who exhaust Vigil™ supply may continue on chemotherapy alone.

Locations

Country	Name	City	State
United States	Mary Crowley Cancer Research Centers	Dallas	Texas

Sponsors (1)

Lead Sponsor	Collaborator
Gradalis, Inc.

Country where clinical trial is conducted

United States, 

References & Publications (1)

Senzer N, Barve M, Kuhn J, Melnyk A, Beitsch P, Lazar M, Lifshitz S, Magee M, Oh J, Mill SW, Bedell C, Higgs C, Kumar P, Yu Y, Norvell F, Phalon C, Taquet N, Rao DD, Wang Z, Jay CM, Pappen BO, Wallraven G, Brunicardi FC, Shanahan DM, Maples PB, Nemunaitis J. Phase I trial of "bi-shRNAi(furin)/GMCSF DNA/autologous tumor cell" vaccine (FANG) in advanced cancer. Mol Ther. 2012 Mar;20(3):679-86. doi: 10.1038/mt.2011.269. Epub 2011 Dec 20. — View Citation

Outcome

Type	Measure	Description	Time frame	Safety issue
Other	Number of Alive Subjects	Survival status of patients after treatment will be determined.	24 months
Primary	Time to Progression (TTP)	Time to progression (TTP) will be determined following Carboplatinum integrated with Vigil vaccine in patients failing standard of care in study CL-PTL 105 or in those not otherwise qualifying after vaccine production. This will be measured from the treatment start date (date of first dose) to either the date the patient is first recorded as having disease recurrence (even if the patient went off treatment because of toxicity), or the date of death if the patient dies due to any causes before progression.	24 months
Primary	Response Rate	Response will be evaluated using the revised Response Evaluation Criteria in Solid Tumors (RECIST) guideline.	Up to 12 months
Secondary	Immune Analysis in Blood	To determine if subjects will have a positive (defined as >10 ELISPOTS from baseline) immune response to Vigil. Blood was collected to compare ELISPOT results from baseline until 30 days after last dose.	Baseline, End of Treatment (30 days after last dose) up to 12 months